Feed LVTX
LV

LAVA Therapeutics N.V.

LVTX · NASDAQ

$1.74 -3.87% (-$0.07)
Market Cap $45.8M
P/E Ratio -
Div. Yield -
ROE 108.07%
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
68 /100
Cheap
P/S 9.17x
P/FCF 3.20x
P/B 3.61x
Growth
100 /100
Growing
Book val. growth 134.99%
EPS growth N/A
FCF growth N/A
Profitability
30 /100
Weak
Gross margin 391.98%
FCF margin 286.37%
Net margin 466.43%
Quality
1 /100
Poor
ROIC 47.45%
Asset turnover 0.10x
ROE 108.07%
Debt
57 /100
Moderate
Debt/Equity 0.00x
Net debt/EBITDA 3.38x
Current ratio 12.27x
Stability
28 /100
Unstable
Beta 0.50x
Profitable years 0
EPS volatility 92.03%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o LVTX
Online

O podjetju

LAVA Therapeutics N.V. (LVTX) is a biopharmaceutical company specializing in the development of novel immunotherapeutic drugs. The company focuses on developing therapies that harness the natural abilities of the immune system to combat cancer and other diseases. LAVA Therapeutics focuses on researching and developing new treatment approaches, utilizing immune system-based technologies such as immune modulators and specific antigens. The company responds to the growing interest in new forms of cancer therapy and treatments based on the immune system. Shares of LAVA Therapeutics N.V. (LVTX) can be an interesting choice for investors tracking the biopharmaceutical and research sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Stephen Allen Hurly

Employees

34

Headquarters

Utrecht

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.